Researchers in the Department of Pharmaceutical Sciences at the Leslie Dan Faculty of Pharmacy, University of Toronto have developed a new technology for liquid biopsy to identify which patients may not respond to standard therapy before it is delivered. (nanotech-now.com)
Toronto, ON, Canada (Scicasts)-- Researchers have developed a new technology for liquid biopsy to identify which patients with prostate cancer may not respond to standard therapy before it is delivered. (scicasts.com)
Ninety percent of children and adults with acute lymphoblastic leukemia (ALL) who had relapsed multiple times or failed to respond to standard therapies went into remission after receiving an investigational personalized cellular therapy, CTL019, developed at the Perelman School of Medicine at the University of Pennsylvania. (sciencedaily.com)